Intellia Therapeutics (NTLA): New Data Implies Clinical Benefit - Wedbush
- AT&T (T) Agrees to Acquire Time Warner (TWX) for More than $80 Billion - WSJ
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Wedbush analyst, David Nierengarten, reiterated his Outperform rating on shares of Intellia Therapeutics (NASDAQ: NTLA) after additional data presented on its TTR program which the analyst thinks should correlate to clinical benefit.
On Thursday NTLA presented data showing they were able to achieve up to 60% editing of transthyretin (TTR) gene in the livers of mice following IV administration, which resulted in up to 80% decrease in TTR serum protein levels; this high editing rate was shown to be consistent across individual mice in a study and across liver lobes.
NTLA had previously presented data showing high levels of dose-dependent TTR editing in the liver cells of mice, and he expects to see further improvements in editing efficiency with continued guide RNA optimization. Although early, these results are meaningful and compare favorably with TTR serum reduction achieved by RNAi programs in development, which he notes are associated with only a transient benefit.
No change to the price target of $38.
Shares of Intellia Therapeutics closed at $22.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Axovant Sciences (AXON) Risk/Reward 'Massively Skewed to the Upside' - Baird
- Wedbush Reiterates Outperform on Pool Corp. (POOL) Following 3Q Report
- Philip Morris Intl (PM) PT Raised to $101 at Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!